Anti-Ranibizumab ELISA Kit

Catalog No.

KAD12602

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Ranibizumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Ranibizumab will be captured by immobilized Ranibizumab. After washing away any unbound substances, a biotin-labeled Ranibizumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Ranibizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Ranibizumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

62.5 - 4,000 ng/mL

Sensitivity

9.17 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	1980.3	509.3	119.3	2293.3	539.8	155.5
Standard deviation	110.1	28.4	6.3	201.6	60.0	20.7
CV (%)	5.6	5.6	5.3	8.8	11.1	13.3

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

Fab-12 variant Y0317,RhuFab,CAS: 347396-82-1

Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis., PMID:40504425

Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration., PMID:40500585

Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review., PMID:40489855

Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway., PMID:40487605

Response to 'Comment on: 'Comparing safety and efficacy of Bevacizumab, Ranibizumab and Ranibizumab biosimilar in Retinopathy of prematurity"., PMID:40483306

Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective., PMID:40481910

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study., PMID:40481786

Modeling the Ocular Pharmacokinetics and Pharmacodynamics of Ranibizumab for Improved Understanding and Data Collection Strategies in Ocular Diseases., PMID:40478563

EFFICACY AND PROGNOSIS OF ANTI-VEGF AGENTS COMBINED WITH PANRETINAL PHOTOCOAGULATION IN DIABETIC RETINOPATHY: A CLINICAL OBSERVATIONAL STUDY., PMID:40466685

Infographic: intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT trial results., PMID:40457097

Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis., PMID:40456283

Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model., PMID:40455045

Several Common Genetic Variations Associate With Functional or Anatomic Effects of Anti-VEGF Treatment in Conditions With Macular Edema., PMID:40455044

Targeting VEGF With 99mTc-Labeled Ranibizumab for Noninvasive Diagnosis of Non-Small Cell Lung Cancer., PMID:40444333

Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy-A Case Report., PMID:40438152

Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial., PMID:40436012

Area Under the Curve Analysis in a Real-World Cohort of Finnish Patients Treated for Neovascular Age-Related Macular Degeneration., PMID:40423616

Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration., PMID:40423060

Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials., PMID:40419166

Subretinal tissue plasminogen activator in polypoidal choroidal vasculopathy-related submacular haemorrhage and exudative retinal detachment., PMID:40409770

Efficacy and safety of prophylactic simultaneous intravitreal moxifloxacin injection with standard intravitreal anti-VEGF injection procedure in cases of cystoid macular edema and macular neovascularization., PMID:40405143

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion., PMID:40405136

[Age-related macular degeneration - Part 2: therapeutic options for AMD]., PMID:40389215

A Study of Visual Outcomes and Spectral Domain Optical Coherence Tomography (SD-OCT) Biomarker Changes in Patients Treated With Ranibizumab for Diabetic Macular Edema in a Tertiary Hospital., PMID:40385737

Effect of simultaneous intravitreal ranibizumab and extended-release dexamethasone injection on patients with naïve versus refractory retinal vein occlusion macular edema: a prospective, multicenter, and interventional open-label study., PMID:40385115

Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab., PMID:40383690

Combining ranibizumab with calcium dobesilate to reduce injection frequency in diabetic macular edema treatment., PMID:40381058

Therapeutic outcomes of ranibizumab for zone ii stage 2 retinopathy of prematurity with plus disease., PMID:40377801

Recurrence of Macular Edema in Branch Retinal Vein Occlusion-A Comparison of Aflibercept and Ranibizumab in a Randomized Trial., PMID:40373873

Sustainable Practices in Anti-VEGF Therapy: A 15-Year Bibliometric Analysis of Ranibizumab for Age-Related Macular Degeneration., PMID:40365539

Planned vs. Performed Treatment Regimens in Diabetic Macular Edema: Real-World Evidence from the PACIFIC Study., PMID:40364151

Dynamic Changes of Aqueous Matrix Metalloproteinases and Imaging Correlation in Retinal Vein Occlusion Following Ranibizumab Therapy., PMID:40359464

Silicone oil microdroplets from syringes with intravitreal anti-vascular endothelial growth factor and complement inhibitor injections., PMID:40359347

OCTA as a reliable prognostic tool for active NVD treated with Panretinal Photocoagulation and/or ranibizumab., PMID:40359330

[Biosimilars of ranibizumab in retinal diseases: new possibilities in ophthalmology]., PMID:40353548

Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis., PMID:40348918

Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis., PMID:40347224

PDVR stage A management: Insights from combined PRP and anti-VEGF treatment outcomes., PMID:40340516

Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy., PMID:40338383

Contributing factors to short-term intraocular pressure elevation following intravitreal anti-VEGF injections., PMID:40335957

Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes., PMID:40335933

Visual fields after anti-vascular endothelial growth factor therapy for retinopathy of prematurity., PMID:40333931

Efficacy of ranibizumab with laser in the treatment of diabetic retinopathy compare with laser monotherapy: A systematic review and meta-analysis., PMID:40331557

Uncommon Therapeutic Approaches for Patients with Recurrent Central Serous Chorioretinopathy: case report and literature review., PMID:40330964

Predictive factors for adherence to intravitreal anti-vascular endothelial growth factor therapy in Palestinian patients with diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration: a retrospective cohort study., PMID:40329243

Beyond the injection: delivery systems reshaping retinal disease management., PMID:40319468

Real-world safety and efficacy of Anti-VEGF treatment in Brazil., PMID:40298749

Effect of Obstructive Sleep Apnea Syndrome on Macular Edema Severity and Response to Intravitreal Ranibizumab in Diabetic Retinopathy and Retinal Vein Occlusion., PMID:40296974

Analysis of the etiology, clinical characteristics and treatment outcomes of choroidal neovascularization in Chinese children and adolescents., PMID:40295924

Document Download

Anti-Ranibizumab ELISA Kit.pdf